Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30735559 | 0.90 | HTR2C (0.62) | HTR2CHTR6CYP1A2 | |
| SCHEMBL19284647 | 0.90 | HTR2C (0.62) | HTR2CHTR6CYP1A2 | |
| Hydrochloric Acid SCHEMBL19284627 | 0.88 | HTR2C (0.64) | HTR2CHTR6CYP1A2 | |
| SCHEMBL30735579 | 0.83 | HTR2C (0.69) | HTR2CHTR6CYP1A2 | |
| SCHEMBL19284644 | 0.83 | HTR2C (0.69) | HTR2CHTR6CYP1A2 | |
| Hydrochloric Acid SCHEMBL19284683 | 0.81 | HTR2C (0.70) | HTR2CHTR6CYP1A2 | |
| SCHEMBL13698221 | 0.80 | HTR6 (0.44) | HTR2CHTR6 | |
| SCHEMBL10085450 | 0.80 | CYP1A2 (0.56) | HTR2CHTR6CYP1A2 | |
| SCHEMBL30449404 | 0.80 | CYP1A2 (0.56) | HTR2CHTR6CYP1A2 | |
| SCHEMBL8878356 | 0.79 | MTNR1A (0.53) | HTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | HTR2C 3/4885HTR6 11/4885CYP1A2 188/4885 |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1B, HTR2C | HTR2C 3/4885HTR6 11/4885CYP1A2 188/4885 |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | HTR2C 3/4885HTR6 11/4885CYP1A2 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.